Dermatologic and Ophthalmic Drugs Advisory Committee Meeting BLA[removed]for Lucentis (ranibizumab injection) Rhea A. Lloyd, M.D. US Food and Drug Administration - Dermatologic and Ophthalmic Drugs Advisory Committee - Document - PDFSEARCH.IO

First Page	Meta Content
	Dermatologic and Ophthalmic Drugs Advisory Committee Meeting BLA[removed]for Lucentis (ranibizumab injection) Rhea A. Lloyd, M.D. US Food and Drug Administration Add to Reading List Open Document File Size: 3,08 MB Share Result on Facebook City South San Francisco / / Company Applicant Information Genentech Inc. / / Event FDA Phase / / MedicalCondition macular edema / Diabetes Mellitus / clinically significant macular edema / diabetic macular edema / retinal vein occlusion / macular degeneration / / Organization Dermatologic and Ophthalmic Drugs Advisory Committee / US Food and Drug Administration / / Person Rhea A. Lloyd / / Position Medical Officer / / Product Ranibizumab Injection / Lucentis / Sham Injection / Year-1 / IgG1 / FVF4170g / / ProvinceOrState California / / Technology laser / / SocialTag Ranibizumab Vascular endothelial growth factor Diabetes Macular degeneration Macular edema Diabetic retinopathy Genentech Ketorolac Off-label use Medicine

Dermatologic and Ophthalmic Drugs Advisory Committee Meeting BLA[removed]for Lucentis (ranibizumab injection) Rhea A. Lloyd, M.D. US Food and Drug AdministrationAdd to Reading List